ASX:RMD - RESMED/IDR UNRESTR Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started A$13.99 -0.02 (-0.14 %) (As of 02/17/2019 04:00 PM ET)Previous CloseA$13.99Today's RangeA$13.98 - A$14.1252-Week RangeA$8.94 - A$12.81Volume2.28 million shsAverage Volume1.82 million shsMarket Capitalization$1.99 billionP/E Ratio44.85Dividend Yield1.34%BetaN/A ProfileDiscussionChartDividendHeadlinesOptions Chain Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides humidifiers, carry bags, and breathing circuits; data communications and control products, such as AirView Diagnostics, EasyCare, ResLink, ResControl, ResControl II, TxControl, ResScan, and ResTraxx modules; U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; and myAir, a patient engagement application that provides sleep data and a daily score based on their previous night's data, as well as offers business management software and services to medical equipment and home health providers. It markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 120 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California. Receive RMD News and Ratings via Email Sign-up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange ASX Industry Medical Instruments & Supplies Sub-IndustryN/A SectorMedical Current SymbolASX:RMD Previous Symbol CUSIPN/A Webwww.resmed.com Phone+1-858-7462400Debt Debt-to-Equity Ratio61.22 Current Ratio2.44 Quick Ratio1.47Price-To-Earnings Trailing P/E Ratio44.85 Forward P/E Ratio34.24 P/E Growth2.49 Sales & Book Value Annual Sales$2.45 billion Price / Sales0.81 Cash FlowA$0.10 per share Price / Cash Flow134.81 Book ValueA$1.37 per share Price / Book10.25Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees5,940 Outstanding Shares142,500,000Market Cap$1.99 billion OptionableOptionable RESMED/IDR UNRESTR (ASX:RMD) Frequently Asked Questions What is RESMED/IDR UNRESTR's stock symbol? RESMED/IDR UNRESTR trades on the ASX under the ticker symbol "RMD." How often does RESMED/IDR UNRESTR pay dividends? What is the dividend yield for RESMED/IDR UNRESTR? RESMED/IDR UNRESTR announced a Interim dividend on Monday, January 28th. Shareholders of record on Thursday, March 14th will be paid a dividend of 0.036 per share on Thursday, March 14th. This represents a dividend yield of 0.25%. The ex-dividend date is Wednesday, February 6th. View RESMED/IDR UNRESTR's Dividend History. Has RESMED/IDR UNRESTR been receiving favorable news coverage? Media coverage about RMD stock has trended somewhat positive this week, InfoTrie reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. RESMED/IDR UNRESTR earned a coverage optimism score of 1.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. Who are some of RESMED/IDR UNRESTR's key competitors? Some companies that are related to RESMED/IDR UNRESTR include Ansell (ANN), Enerplus (ERF), Nanosonics (NAN), TransEnterix (TRXC), CRH Medical (CRH), Clover (CLV), CRH Medical (CRHM), Bovie Medical (BVX), Bovie Medical (BVX), InfuSystem (INFU), Daxor (DXR), TSO3 (TOS), IsoRay (ISR), IsoRay (ISR) and Retractable Technologies (RVP). Who are RESMED/IDR UNRESTR's key executives? RESMED/IDR UNRESTR's management team includes the folowing people: Mr. Michael J. Farrell BE, SM, MBA, CEO & Director (Age 47)Mr. Robert A. Douglas, Pres & COO (Age 59)Mr. Brett A. Sandercock, Chief Financial Officer (Age 52)Mr. David B. Pendarvis, Chief Admin. Officer, Global Gen. Counsel & Sec. (Age 60)Mr. James Hollingshead, Pres of Sleep Bus. (Age 56) What is RESMED/IDR UNRESTR's stock price today? One share of RMD stock can currently be purchased for approximately A$13.99. How big of a company is RESMED/IDR UNRESTR? RESMED/IDR UNRESTR has a market capitalization of $1.99 billion and generates $2.45 billion in revenue each year. RESMED/IDR UNRESTR employs 5,940 workers across the globe. What is RESMED/IDR UNRESTR's official website? The official website for RESMED/IDR UNRESTR is http://www.resmed.com. How can I contact RESMED/IDR UNRESTR? RESMED/IDR UNRESTR's mailing address is 9001 Spectrum Center Blvd, SAN DIEGO, CA 92123-1438, United States. The company can be reached via phone at +1-858-7462400. MarketBeat Community Rating for RESMED/IDR UNRESTR (ASX RMD)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 63 (Vote Outperform)Underperform Votes: 68 (Vote Underperform)Total Votes: 131MarketBeat's community ratings are surveys of what our community members think about RESMED/IDR UNRESTR and other stocks. Vote "Outperform" if you believe RMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RMD will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/17/2019 by MarketBeat.com StaffFeatured Article: What Is An Exchange-Traded Fund (ETF)?